The prime objective of GlobalNewborn and Prenatal Genetic Testing Market report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Impact of Covid-19 in Newborn and Prenatal Genetic Testing Market: Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Newborn and Prenatal Genetic Testing market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Download FREE Sample Copy of Newborn and Prenatal Genetic Testing Report @https://www.crediblemarkets.com/sample-request/newborn-and-prenatal-genetic-testing-market-51974

By Market Players:Perkin ElmerAriosa DiagnosticsAgilent Technologies, Inc.Verinata HealthIllumina, Inc.Sequenom, Inc.CapitalBio MedLabNatera, Inc.Bio-Rad Laboratories, Inc.BGI

By TypePCRFISHaCGHNIPTMSS

By ApplicationHospitalClinicOthers

Geographically, the detailed analysis of consumption, revenue, and market share and growth rate, historic and forecast of the following regions:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Enquiry before buying this report @ https://www.crediblemarkets.com/enquire-request/newborn-and-prenatal-genetic-testing-market-51974

Some Points from Table of Content

Covid-19 Impact on Global Newborn and Prenatal Genetic Testing Industry Research Report 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026

Chapter 1 Report OverviewChapter 2 Global Newborn and Prenatal Genetic Testing Market Trends and Growth StrategyChapter 3 Global Newborn and Prenatal Genetic Testing Market Players ProfilesChapter 4 Global Newborn and Prenatal Genetic Testing Market Competition by Market PlayersChapter 5 Global Newborn and Prenatal Genetic Testing Production by Regions (2015-2020)Chapter 6 Global Newborn and Prenatal Genetic Testing Consumption by Region (2015-2020)Chapter 7 Global Newborn and Prenatal Genetic Testing Production Forecast by Regions (2021-2026)Chapter 8 Global Newborn and Prenatal Genetic Testing Consumption Forecast by Regions (2021-2026)Chapter 9 Global Newborn and Prenatal Genetic Testing Sales by Type (2015-2026)Chapter 10 Global Newborn and Prenatal Genetic Testing Consumption by Application (2015-2026)Chapter 11 Global Newborn and Prenatal Genetic Testing Manufacturing Cost AnalysisChapter 12 Global Newborn and Prenatal Genetic Testing Marketing Channel, Distributors, Customers and Supply ChainChapter 13 Analysts Viewpoints/ConclusionsChapter 14 Disclaimer

Grab Maximum Discount on Newborn and Prenatal Genetic Testing Market Research Report @https://www.crediblemarkets.com/discount-request/newborn-and-prenatal-genetic-testing-market-51974

Points Covered in The Report

About Credible Markets

Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Ask for customization @https://www.crediblemarkets.com/custom-research

The rest is here:
Newborn and Prenatal Genetic Testing Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 - Bulletin Line

Recommendation and review posted by Bethany Smith

This article concerns the development of advanced therapies and the challenges and complexities of getting them through the developmental pathway, which the authors call the trip. The authors examine at strategic levels the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges (trip hazards) for cell and gene therapies and offer bench-to-bedside and chemistry, manufacturing, and controls (CMC) considerations and advise on nonclinical and clinical investigations. They conclude that early contact with regulators can help avoid trip hazards.IntroductionThe advanced therapy sector has grown rapidly, reflecting the tremendous interest for these complex biologic products with potentially curative effect. Advanced therapy products, including cell and gene therapies, as well as tissue-engineered products, have shown great promise for addressing medically unmet needs, particularly for orphan diseases and in oncology. The Alliance for Regenerative Medicine reported a 32% growth in clinical investigations of regenerative medicine products from 2014 to 2018.1 Currently, there are more than 2,000 product candidates under development. Although forecasts of compound annual growth rates and predicted market values vary among different reports, the cell and gene therapy market was valued at more than US$1 billion in 2018 and by 2025, is likely to exceed US$10 billion.2However, product development for advanced therapies still poses a number of potential trip hazards, even though supporting guidance has matured to a good level. Potential challenges may occur at all stages of nonclinical, process, and clinical product development. These hazards include, but not limited to, technology transfer; CMC; clinical investigations; and stage-appropriate good practice considerations. It is paramount to be aware of trip hazards before they occur, because they can equate to time- and cost-related program impacts.In this article we will highlight, at a strategic level, the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges (trip hazards) for cell and gene therapies, in which things frequently go wrong, and sometimes critically so. For simplicity, tissue-engineered products are not covered in the scope of this article but share certain commonality with cellular-based products.What makes advanced therapies different?It is imperative to understand the product itself for the successful development of any therapeutic product. Small molecules are very well understood because they are a single molecule of low-molecular weight and produced through a defined chemical synthesis that yields mathematically identical copies. As such, they can be straightforwardly characterized. Biologics, such as monoclonal antibodies, cytokines, and other recombinant products, can also be generally well defined but they have higher structural complexity and posttranslational modifications. The fact that these are manufactured in living producer cells also reduces the ability to control production of identical copies. There is, therefore, inherent heterogeneity in the product, making biologics generally more sensitive to external conditions and stability. Many of the traits associated with biologics also apply to advanced therapies. So, what makes them so different?Advanced therapies add an additional layer of complexity to the traditional biologic product. These definitions are paraphrased from the European Medicines Agency (EMA)3 and US Food and Drug Administration (FDA)4 definitions for cell and gene therapies:

CMC considerationsProduct diversity is a key point for understanding advanced therapies in that there is greater multiplicity of cellular/gene/tissue products. Therefore, a one-size-fits-all approach does not work precisely, with there often being specific and novel nuances across products.The goal of any drug product development is to manufacture a product to a predefined quality and to realize a process that is robust and reproducible. The objective is to deliver a product that meets quality, safety, and efficacy requirements.For any drug product development program, CMC is directly on the critical path. Although it may be possible to compact some time and cost aspects through strategic consideration, the wake-up call is that there are no shortcuts for the attributes of quality and safety. The CMC is the clinical product, so it must be pitch perfect. Advanced therapies have more complex parts, with which developers must deal in terms of their characterization, manufacture, controls, and applied specifications. All these factors need adequate development time to apply the appropriate measures, or else the entire development program runs the risk of stumbling and falling at some point thereafter.Some exemplary common CMC consideration points (not exhaustive) where cell therapy (CT) and gene therapy (GT) programs can be tripped are:Manufacturing process

It is important to note that these statutory timelines may not accurately apply to all GMO-based products during the current COVID-19 health emergency. In June 2020, the European Commission issued a proposal to relax requirements specifically for clinical trials exploring GMO-containing COVID-19 treatments and vaccines. The proposal suggests allowing temporary derogation from requirements of Directives 2001/18/EC and 2009/41/EC for products to treat or prevent COVID-19 for the duration of the pandemic.8 This temporary relaxation of requirements does not apply to treatments for other diseases. Readers are advised to enquire with individual national agencies about any changes in process and timelines during the COVID-19 pandemic because these may be updated frequently.LogisticsWhile additional approval requirements on the critical path might directly affect the clinical trial start-up time, various other logistical considerations at site level can also influence the timeline and/or overall feasibility of the trial. The logistical challenges will depend on the type of product. For example, products based on living cells, such as cell therapies and cell-based gene therapies, have an inherently short shelf life at ambient temperatures so careful consideration should be given to transportation logistics from the site of the source biopsy to the manufacturing facility, and to the return to the clinical site for autologous/allogeneic patient administration. Handling of the starting material (such as the patients own cells for an autologous cell-based therapy) and the final drug product may require use of specialized equipment, such as laminar flow hoods, cryogenic storage, special centrifuges. Staff must be appropriately trained to use the equipment and handle the products. Moreover, certain advanced therapy products require the co-use of specific medical devices.The preceding considerations are a small fraction of the overall logistical requirements for conducting a global advanced therapy clinical study. Contract research organizations, or CROs, have a key role in providing training for nurses, physicians, pharmacists, and other site staff, as well as providing clinical logistics coordination to oversee patient and sample transportation and tracking in close collaboration with sites and sponsors.

Patient counseling and eligibilityGenetic counseling as a prerequisite to genetic testing to evaluate patient eligibility for a clinical trial is an additional steppingstone in numerous countries. Some countries may require the general availability of counseling, whereas others mandate genetic counseling before genetic testing can be done. Also, specially trained personnel might be necessary to conduct the genetic testing. The specific national requirements should be factored in during clinical trial planning to ensure availability of qualified personnel as required and possibly included in the informed consent forms.Regulatory authority guidanceAdvanced therapy product development must follow all good practice requirements for small-molecule and biologic products. However, owing to the complexity of the products and added risks to clinical trial subjects, there are further specific requirements for advanced therapies. In addition, clinical trial design may need to encompass specifically tailored trial designs including single-arm studies and/or study designs using a synthetic control arm. In many cases, it is not feasible and/or ethical to conduct standard double-blind studies for advanced therapies because of the invasive methods used to extract human source material or administer the advanced therapy product, and ease of distinction between placebo and investigational product.Furthermore, all advanced therapies require extended, long-term follow-up periods and/or the establishment of registries. The use of tailored trial designs is critical to ensure a time and cost-effective development program leading to patient and payer acceptance.Global regulators recognize the value of advanced therapies, particularly given their potentially curative effect, and they have provided ample guidance for all stages of product development. Recent guidance on clinical study design also addresses the need for deviation from traditional study designs to those involving more real-world data. Available key guidance documents in the European Union and the US will be the subject of an upcoming publication.Early interactions with regulatory and health authorities is encouraged to obtain supportive direction and acknowledgment of the approaches to be taken in the development program. Key regulators have pointed out it is pertinent to understand the product and its aims as early as possible to provide proactive advice with this further alluding to the avoidance of common trip hazards. This also further opens the door to priority advanced therapy support vehicles, such as EMA and FDA early scientific advice (e.g. INTERACT, pre-investigational new drug meetings), participation in the regenerative medicine advanced therapy and the EMAs priority medicines schemes, where possible, and other more widely available mechanisms supporting efficient product development.ConclusionAdvanced therapies are a dynamic and fast-growing sector of the pharmaceutical industry. Due to their additional complexity over traditional biologics, they require added ingenuity in line with the particular nature of the cell or gene therapy product type, demanding a carefully considered technical and regulatory development approach to anticipate and mitigate potential risks upfront.Regulatory agencies have implemented additional requirements for overall product development, the conduct of clinical trials and/or data needed for product approval. It is therefore imperative to conduct an in-depth regulatory intelligence collection with national requirements for countries intended to be included in the clinical trial. The investigation of associated timelines, particularly for GMO-based products, will also ensure a country selection that supports an achievable timeline for study start-up in a global environment.Developers of advanced therapies also need to include strategies beyond the clinical development to ensure patient access with a sound understanding of not only regulatory expectations but also the health technology assessment/payer evidence requirements to ascertain approval and reimbursement. The important take-home messages are to begin with the end in mind and to develop sound technical and regulatory strategies, to better anticipate and avoid many of the trip hazards that could prove costly, both in time and money, all of which could critically affect the overall clinical study program.AbbreviationsCMC, chemistry, manufacturing, and controls; CT, cell therapy; EMA; European Medicines Agency; EU, European Union; FDA, [US]Food and Drug Administration; GT, gene therapy; GMO, genetically modified organisms; NIH, National Institutes of Health; RAC, Recombinant DNA Advisory CommitteeReferencesAll websites were accessed on 31 July 2020.

Continue reading here:
Advanced therapies: 'Trip hazards' on the development pathway - Regulatory Focus

Recommendation and review posted by Bethany Smith

The Report Titled On DTC Genetic Testing Market includes Market Size (Production, Consumption, Value and Volume), Upstream Situation, Market Segmentation, DTC Genetic Testing Market Segmentation, Price & Cost And Industry Environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The prime objective of this DTC Genetic Testing market report is to help the user understand the market in terms of its Definition, Segmentation, Market Potential, Influential Trends, and the Challenges that the Market Is Facing.

The DTC Genetic Testing Market profile also contains descriptions of the leading topmost manufactures/players like (23andMe, Ancestry, Color, EasyDNA, Family Tree DNAGene by Gene, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA, MapMyGenome, MyHeritage, Pathway Genomics)which including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.

Get Free Sample PDF (including full TOC, Tables and Figures)of DTC Genetic Testing[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2423654

Scope of DTC Genetic Testing Market:Direct-to-consumer genetic testing is different: these genetic tests are marketed directly to customers via television, print advertisements, or the Internet, and the tests can be bought online or in stores. Customers send the company a DNA sample and receive their results directly from a secure website or in a written report. Direct-to-consumer genetic testing provides people access to their genetic information without necessarily involving a healthcare provider or health insurance company in the process.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Targeted Analysis Single Nucleotide Polymorphism (SNP) Chips Whole Genome Sequencing (WGS)

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of DTC Genetic Testing for each application, including-

Carrier Testing Predictive Testing Ancestry and Relationship Testing Nutrigenomics Testing Others

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2423654

Geographically, the report includes the research on production, consumption, revenue, DTC Genetic Testing market share and growth rate, and forecast (2020-2026) of the following regions:

Key Developments In The DTC Genetic Testing Market:

To describe DTC Genetic Testing Introduction, product type and application, market overview, DTC Genetic Testingbmarket analysis by countries, market opportunities, market risk, market driving force;

To analyze the manufacturers of DTC Genetic Testing market, with profile, main business, news, sales, price, revenue and market share in 2016 and 2020;

To display the competitive situation among the top manufacturers in North America, with sales, revenue and DTC Genetic Testing market share in 2016 and 2020;

To show the market by type and application, with sales, price, revenue,DTC Genetic Testing market share and growth rate by type and application, from 2013 to 2020;

To analyze the key countries by manufacturers, Type and Application, covering United States , Canada and Mexico, with sales, revenue and DTC Genetic Testing market share by manufacturers, types and applications;

DTC Genetic Testing market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2020 to 2026;

To analyze the DTC Genetic Testing market manufacturing cost, key raw materials and manufacturing process etc.

To analyze the industrial chain, sourcing strategy and downstream end users (buyers);

To describe DTC Genetic Testing market sales channel, distributors, traders, dealers etc.

To describe DTC Genetic Testing market Research Findings and Conclusion, Appendix, methodology and data source.

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
DTC Genetic Testing Market 2020-2026: Analysed By Business Growth, Development Factors, Applications, And Future Prospects - Market Research...

Recommendation and review posted by Bethany Smith

You could be Jadens cure

Jaden lives in Hilo, just turned 18 and has been diagnosed with a blood cancer. He is in dire need of a bone marrow or blood stem transplant. You could be Jadens cure.

If you are between the ages of 18-44 you can register online and add your name to the Hawaii marrow donor registry. A sample kit is mailed to you, you touch one swab in your mouth and send it back. Your tissue type is registered for worldwide use until you reach age 61.

I registered in Flint, Michigan, in 2006. I got the call in 2010 here in Kona at age 60. My donation of stems cells was done at St. Francis in Honolulu. It was totally painless and easy and the stem cells were sent to the mainland where the patient was cured of caner. The BeTheMatchHawaii health care professionals at St. Francis are very good, very friendly and like family to all the donors and patients.

Every three minutes there is a new blood or bone cancer diagnosis on our planet. Every one should go to http://www.BeTheMatchHawaii.org, where all of your questions can be answered and most importantly you can get tested and registered. You have the opportunity to change the world and save a life. How could anybody refuse to offer the gift of life when you learn that you are a match?

Since 1990, Hawaii citizens have donated to 468 cancer patients worldwide: The U.S., Brazil, Korea, Japan, Italy, Poland, actually 28 countries so far, including eight patients in Hawaii.

Please check it out, sign up and spread the word to all of your family, friends, coworkers, classmates, etc. Jaden is counting on us and you may never be match for any cancer patient, but if you are a match you can literally give someone the gift of life. How cool is that?

Larry Boucher

Kailua-Kona

Letters policy

Letters to the editor should be 300 words or less and will be edited for style and grammar. Longer viewpoint guest columns may not exceed 800 words. Submit online at http://www.westhawaiitoday.com/?p=118321, via email to letters@westhawaiitoday.com or address them to:

Editor

West Hawaii Today

PO Box 789

Kailua-Kona, HI 96745

Continued here:
Letters to the Editor: Aug. 3, 2020 - West Hawaii Today

Recommendation and review posted by Bethany Smith

DARZALEX SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX (daratumumab)

TORONTO, Aug. 4, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX SC (daratumumab), a new subcutaneous formulation of daratumumab.1 DARZALEX SC is approved in four regimens across five indications in patients with multiple myeloma, most notably newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX SC can be administered over approximately three to five minutes, significantly less time than intravenous (IV) DARZALEX, which is administered over hours.2 DARZALEX SC is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma.

In the Phase 3 COLUMBA study published in The Lancet, DARZALEX SC demonstrated a consistent overall response rate (ORR) and pharmacokinetics and a similar safety profile compared with IV DARZALEXin patients with relapsed or refractory multiple myeloma. In addition, there was a nearly two-thirds reduction in systemic administration-related reactions (ARRs) for DARZALEX SC compared to IV DARZALEX(13 per cent vs. 34 per cent, respectively).3

"DARZALEX has become a backbone therapy in the treatment of multiple myeloma, supported by a robust body of evidence in both the frontline and relapsed and refractory settings," says Dr. Darrell White, Hematologist, Queen Elizabeth II Health Sciences Centre, Halifax. "With this new subcutaneous formulation, not only is treatment much more convenient for patients, but it will also play a very important role in reducing wait times and the burden on our busy healthcare system, especially during this time."

The approval is based on data from the Phase 3 COLUMBA and Phase 2 PLEIADES studies.4,5In the COLUMBA study, the ORR was non-inferior for patients taking DARZALEX SC as monotherapy compared to those taking IV DARZALEXas monotherapy (41 per cent vs. 37 per cent, respectively).6 Additionally, in the Phase 2 PLEIADES study evaluating the efficacy and safety of DARZALEXSC in combination therapies, objective responses were demonstrated in combination with bortezomib, melphalan and prednisone (D-VMP) in newly diagnosed transplant ineligible patients. In addition, objective responses were demonstrated in combination with lenalidomide and dexamethasone (D-Rd) in relapsed or refractory patients who received one prior line of therapy.7In a pooled safety population of 490 patients who received DARZALEXSC as monotherapy or in combination, the ARR rate was 11 per cent.8

DARZALEX SC is approved in all current IV indicationsincluding (1) in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant, (2) in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, (3) in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, and (4) as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.9

Active discussions are ongoing with public insurers to determine how DARZALEX SC can be made accessible for both relapsed or refractory patients as well as newly diagnosed, transplant ineligible patients.

"This approval exemplifies Janssen's mission and commitment to bringing together passion, science and ingenuity to advance novel solutions for patients," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC.

About the COLUMBA Study The randomised, open-label, multicenter Phase 3 COLUMBA study included 522 patients (median age of 67 years) with multiple myeloma who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both a PI and an ImiD. In the arm that received DARZALEX SC (n=263), patients received a fixed dose of DARZALEX SC 1,800 milligrams (mg), co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) 2,000 Units per milliliter (U/mL), subcutaneously weekly for Cycles 1 2, every two weeks for Cycles 3 6 and every four weeks for Cycle 7 and thereafter. In the IV DARZALEXarm (n=259), patients received DARZALEXfor IV infusion 16 milligrams per kilogram (mg/kg) weekly for Cycles 1 2, every two weeks for Cycles 3 6 and every four weeks for Cycle 7 and thereafter. Each cycle was 28 days. In the arm that received DARZALEX SC, it was given in a fixed volume of 15 mL over three to five minutes; the median injection time was five minutes. In the arm that received the IV administration, the median durations of the first, second and subsequent IV DARZALEXinfusions were 7.0, 4.3 and 3.4 hours, respectively. Patients in both arms continued treatment until disease progression or unacceptable toxicity.10,11

About the PLEIADES Study The non-randomised, open-label, parallel assignment Phase 2 PLEIADES study included adults with multiple myeloma, including 67 patients with newly diagnosed multiple myeloma who were treated with 1,800 mg of DARZALEX SC in combination with bortezomib, melphalan, and prednisone (D-VMP) and 65 patients with relapsed or refractory disease who were treated with 1,800 mg of DARZALEX SC plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D- Rd cohorts was overall response rate.12

About DARZALEXand DARZALEX SCDARZALEX is the first CD38-directed monoclonal antibody (mAb) approved to treat multiple myeloma and in 2020, DARZALEX SC (daratumumab) follows as the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma.13It binds to CD38,a surface protein highly expressed across multiple myeloma cells.14 DARZALEX induces tumor cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).15DARZALEX has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response.16

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX. Janssen Inc. commercializes DARZALEX and DARZALEX SC in Canada. For full Prescribing Information and more information about DARZALEX and DARZALEX SC, please visit http://www.janssen.com/canada.

About Multiple MyelomaMultiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.17 When damaged, these plasma cells rapidly spread and replace normal cells with tumors in the bone marrow. In 2020, it is estimated that 3,400 Canadians will be diagnosed with multiple myeloma and there will be 1,600 deaths associated with the disease.18 While some patients with multiple myeloma have no symptoms in the early stages, patients are diagnosed due to symptoms that can include bone disease or pain, anemia, calcium elevation, and kidney problems.19

About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at http://www.janssen.com/canada. Follow us at @JanssenCanada. Janssen Inc. is a member of the Janssen Pharmaceutical Companies of Johnson & Johnson.

*All trademark rights used under license. **Dr. White was not compensated for any media work. He has been compensated as a consultant.

Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DARZALEX SC. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

References:

1

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

2

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

3

Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.

4

Mateos M-V et al. Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (pts) With Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. 2019 American Society of Clinical Oncology Annual Meeting. June 2019.

5

Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.

6

Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.

7

Chari A, M. J., McCarthy H, et al Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy: PLEIADES study update. Poster presented at: 61st American Society of Hematology (ASH) Annual Meeting. Orlando, FL.

8

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

9

[DARZALEX SC Product Monograph, Janssen Inc.,July 29, 2020]

10

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

11

Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.

12

Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.

13

Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.

14

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

15

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

16

[DARZALEX SC Product Monograph, Janssen Inc., July 29, 2020]

17

Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after therapywith IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.

18

Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma." Available at: https://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/statistics/?region=on.Accessed June 2020.

19

Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma." Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/signs-and-symptoms/?region=on.Accessed June 2020.

SOURCE Janssen Inc.

For further information: Media Contact: Janssen Inc., Jennifer McCormack, Office: (416) 382-5121; Investor Contact: Jennifer McIntyre, Office: (732) 524-3922

http://www.janssen.ca/

Read the original:
Janssen Announces Health Canada Approval of DARZALEX* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Canada...

Recommendation and review posted by Bethany Smith

Adrenoleukodystrophy (ALD) is a rare genetic condition that causes the buildup of very-long-chain fatty acids (VLCFAs) in the brain. The defective gene in ALD, commonly referred to as a genetic mutation, can cause several different but related conditions: adrenomyelopathy (AMN), Addisons disease, and the most common and most devastating form cerebral ALD. Cerebral ALD strikes boys between ages 4 and 10, leading to permanent disability and death usually within four to eight years.

Signs and symptoms of the adrenomyeloneuropathy type appear between early adulthood and middle age. Affected individuals develop progressive stiffness and weakness in their legs (paraparesis), experience urinary and genital tract disorders, and often show changes in behavior and thinking ability. Most people with the adrenomyeloneuropathy type also have adrenocortical insufficiency. In some severely affected individuals, damage to the brain and nervous system can lead to an early death.

For detailed analysis on the symptoms of Global Adrenoleukodystrophy Pipeline Analysis browse through https://univdatos.com/report/global-adrenoleukodystrophy-pipeline-analysis-2019

The diagnosis of the disease includes genetic counseling, differential diagnosis, biochemical and molecular diagnosis. Genetic counseling must be offered to the parents of affected boys, adult males, and women with X-ALD and their family to detect: carriers who can be offered prenatal diagnosis, and asymptomatic or pre-symptomatic men or women who can benefit from therapeutic interventions. Regular follow-up in presymptomatic males can prevent serious morbidity and mortality.

Despite significant mortality risk, allogeneic HCT remains the only therapeutic intervention that can arrest the progression of cerebral demyelination in X-ALD, provided the procedure is performed very early, i.e., when affected boys or men have no or minor symptoms due to cerebral demyelinating disease. In the future, transplantation of autologous hematopoietic stem cells that have been genetically corrected with a lentiviral vector before re-infusion might become an alternative to autologous HCT, once the very encouraging results obtained in the first two treated patients would have been extended to a larger number of patients with cerebral X-ALD.

For detailed analysis on the management in Global Adrenoleukodystrophy Pipeline Analysis browse through https://univdatos.com/report/global-adrenoleukodystrophy-pipeline-analysis-2019

There are currently only two available treatments for childhood cerebral ALD: Lorenzos oil and stem cell transplantation, using either umbilical cord stem cells or bone marrow stem cells. Both treatment approaches have shown promise and been effective for some boys with ALD, but they also both have drawbacks. The therapeutic pipeline of Adrenoleukodystrophy consists of approximately 9+ products in different stages of development. Currently, 3+ drugs are in Phase III development and major drugs are in the late stage.

Request for Sample of the report browse through https://univdatos.com/request_form/form/170

Some of the key players include Applied Genetic Technologies Corporation; Bluebird bio; Magenta Therapeutics; MedDay Pharmaceuticals; Minoryx Therapeutics; NeuroVia; Orpheris; ReceptoPharm; SOM Biotech; and Viking Therapeutics. Several M&As along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.

Top Company Profiles

Feel free to contact us for any queries https://univdatos.com/request_form/form/170

Customization Options:

The Adrenoleukodystrophy pipeline analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.

About Us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. Rigorous secondary and primary research on the market is our USP, hence information presented in our reports is based on facts and realistic assumptions. We have worked with 200+ global clients, including some of the fortune 500 companies. Our clientele praises us for quality of insights, In-depth analysis, custom research abilities and detailed market segmentation.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Continue reading here:
Global Adrenoleukodystrophy Treatment Trends and Highlights - Bulletin Line

Recommendation and review posted by Bethany Smith

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.

The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived made from substances such as proteins and antibodies found in living things and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.

These are each powerful examples of how next-generation novel therapies translated here at Dana-Farber from bench to bedside are further improving outcomes for our patients, and at a remarkable pace, says Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber.

Following a Dana-Farber-led clinical trial, the FDA recently approved the novel drug isatuximab in combination with pomalidomide and dexamethasone for adults with relapsed or refractory (non-responsive) myeloma who have received at least two prior therapies, including lenalidomide and drugs known as proteasome inhibitors. The drug went into trials after laboratory work by Dana-Farbers Yu-Tzu Tai, PhD, and Kenneth Anderson, MD, showed it was active against myeloma cells. In the clinical trial, the three-drug combination lowered the risk that the disease would progress by 40%, compared to pomalidome and dexamethasone alone.

Dana-Farber investigators conducted laboratory research and led the first clinical trial of the drug melflufen plus dexamethasone in patients with relapsed or refractory myeloma. Melflufen is a peptide conjugate drug made of a stub of protein, or peptide, joined to a chemotherapy agent and delivers a toxic payload directly to myeloma cells in a selective, time-sparing approach.

Results from an early-phase clinical trial published in Lancet Oncology showed the drug is active in patients with myeloma and is safe at recommended doses. Unlike the previously used standard drug melphalan, it doesnt cause mucositis inflammation of membranes within the digestive tract or hair loss. The results prompted investigators to launch two larger trials, some of whose results are being processed and are due to be published soon.

In a major study published in Blood, Dana-Farber researchers and their associates found that in patients newly diagnosed with myeloma who are eligible for a stem cell transplant, adding the drug daratumumab to the standard three-drug regimen produced more responses, and deeper responses, than in patients receiving the three-drug therapy alone.

Dana-Farber researchers were involved in the development and initial testing of the drug belantamab mafodotin, which has shown considerable promise in clinical trials and has been granted priority review for approval by the FDA.

An antibody conjugate drug consisting of an antibody that specifically targets myeloma cells and an agent that disrupts cell division, its use was informed by a preclinical trial at Dana-Farber involving Yu-Tzu Tai, PhD, and Kenneth Anderson, MD. Balantamab mafodotin was tested in studies led by Paul Richardson, MD, in patients with relapsed or refractory multiple myeloma whose disease continued to worsen after a stem cell transplant, chemotherapy, or other treatment. In the DREAMM-1 and -2 trials, the drug showed strong anti-myeloma activity with manageable side effects.

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next-generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and an first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma.

Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next-generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat.

He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple Myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by the second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.

Read the original:
Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma - Dana-Farber Cancer Institute

Recommendation and review posted by Bethany Smith

Dear Doctor: What's the connection between the novel coronavirus and the thymus gland? A friend of ours who is a doctor says it's probably what keeps young kids from getting so sick. I've never even heard of the thymus. What does it have to do with coronavirus?

Dear Reader: From the earliest days of the novel coronavirus pandemic, the data revealed a puzzling disparity. Older adults were at increased risk of grave illness when infected with the virus, but children seemed to have a certain level of protection. And while it has since become clear that children can indeed become seriously ill if they become infected, they do so at far lower rates than adults. The reasons for this are still being investigated, but some researchers have recently suggested the role of the thymus gland as a possible factor.

If you place your finger at the notch at the top of your breast bone and draw a vertical line downward a few inches, you've traced the location of your thymus. It's made up of two roughly triangular lobes, which sit behind the breastbone and between the lungs. The thymus has several functions, but perhaps its most important role is to help produce the cells that will become T-lymphocytes, or T-cells. (The "T" stands for thymus-derived.) These are white blood cells that protect the body from bacteria, fungi, viruses and other pathogens.

T-cells, which are the ninjas of the immune system, start out in the bone marrow as stem cells. The immature stem cells exit the marrow, move through the blood and enter a specific region of the thymus. There, they undergo a complex process that teaches them how to recognize a wide range of potentially dangerous and deadly invaders. As T-cells, their job is to circulate throughout the body and, when they encounter the molecular signature of the pathogen they've been trained to recognize, to attack. T-cells also activate other immune cells, produce proteins known as cytokines and have a role in regulating immune response.

The thymus is unique in that it reaches maturity in utero and is at its largest and most active in children. Starting at puberty, it gradually becomes less active, and the glandular tissue begins to shrink. This continues throughout a person's life. By the time someone has reached their mid-60s, the thymus is largely inactive. By their mid-70s, the gland has been mostly replaced with fat. This decrease in thymus function is believed to be one of the reasons that, in their later years, older adults become more susceptible to disease and infection.

Emerging research into COVID-19 has shown a marked decrease in the number of T-cells in some gravely ill patients. Scientists are now asking whether age-related thymus decline, which means T-cells aren't quickly replaced, may play a role in the severity of illness seen in older adults. The flip side of this is whether, due to their robust production of T-cells, children's immune systems are able to stay one step ahead of the novel coronavirus. It's only a working theory, but it shows promise, and research into how this may affect and inform treatment continues.

Eve Glazier, M.D., MBA, is an internist and associate professor of medicine at UCLA Health. Elizabeth Ko, M.D., is an internist and assistant professor of medicine at UCLA Health.

The rest is here:
Theory suggests thymus plays role in severity of COVID - Times Record

Recommendation and review posted by Bethany Smith

Companies, Organizations Needed to Host Events

MONTVALE, NJ Because of the current, nationwide surge in COVID-19 infections throughout the Sun Belt, along with the constant importance of bolstering the local blood supply, theres now significant need for residents to donate blood and, if possible, convalescent plasma.

The nonprofit, blood-collection organization Vitalantis offering an open-to-the-public Mark Spatola Memorial Drive on Tuesday, August 11 from 2 p.m. to9 p.m. at St. Agnes Parish Center, 55 South Avenue,Atlantic Highlands.

Sign Up for Belmar/Lake Como Newsletter

Our newsletter delivers the local news that you can trust.

You have successfully signed up for the TAPinto Belmar/Lake Como Newsletter.

Vitalant is also seeking companies and organizations throughoutMonmouth Countyto host blood donation events. Information on hosting a donation event is available by clicking here.

Individuals who have recovered from COVID-19 are urged to donate blood plasma. Known as convalescent plasma, this blood component contains antibodies that may provide seriously ill patients an extra boost in fighting the disease.

Vitalant is providing an antibody test which is authorized by the U.S. Food and Drug Administration to all donors; results will be available in private, online donor accounts, approximately two weeks after a donation.There is also a great need for blood platelets small cells in the blood that form clots to prevent bleeding, while also helping with anemia and low blood countsand type O-negative,the universal blood type.

To promote the increase of blood, convalescent plasma, and platelet donations,regular event host companies and organizations many of which put their events on pause due to the pandemic are asked toconsider returning to a consistent schedule of donation events.

FEMA has specifically identified blood donation as an essential and integral component of the emergency support function. Of note, coronavirus cannot be transferred through the blood. And, as always, the blood collection process is safe with noimpact on the donor's immune system. Vitalant staff follows rigorous safety and disinfection protocols at its blood drives and donation centers and have always required individuals to be in good health to donate blood.

Vitalant also maintains four New Jersey blood centers, with hours and street addresses as follows:

Healthy individuals age 16 or older, who weigh at least 110 pounds, may donate blood; 16- and 17-year-olds must have proof of birth date and signed consent forms, either in English or Spanish. Donors should eat a moderate meal prior to donating, and also bring identification featuring their signature.

On occasion, last-minute changes to scheduling for a donation event will occur. As a result, it is recommended that anyone planning to donate blood at a Vitalant donation event call 201-251-3703, toll free, to confirm timing and location details. Additional information about donating blood is also available by visitingwww.vitalant.org.

About Vitalant in New Jersey

A not-for-profit organization that supplies blood and blood products to hospitals in the New Jersey/New York region, Bergen County-based Vitalant (previously Community Blood Services) has been devoted to serving the communitys transfusion medicine needs since 1953. Donations of blood and blood products, umbilical cord blood, stem cells, and bone marrow help to join individuals, organizations, businesses, and entire communities together in partnership to help save lives.

About Vitalant

Arizona-based Vitalant is among the nations oldest and largest transfusion medical organizations in the U.S. Founded in 1943, its blood centers division serves some 700 hospitals across the United States. A founding member of Americas Blood Centers and the AABB (formerly the American Association of Blood Banks), Vitalant also operates biological products distribution services, a quality consulting group, and a world-renowned transfusion medicine research institute. It also is a partner in the operation of high-volume donor testing laboratories.

Read the original here:
Vitalant to Hold Blood Donation Drive on August 11 in Atlantic Highlands - TAPinto.net

Recommendation and review posted by Bethany Smith

CRISPR is a catchy acronym that originally described a naturally occurring gene editing tool, derived from a bacterial defense mechanism against viruses. Its the name on everybodys lips in the intersecting realms of science, medicine, ethics, and politics. From the moment of its discovery, CRISPR-Cas9 looked like a miraculous solution to all of the problems that gene editing efforts have experienced over decades of trial and error. This revolutionary new gene editing technique has opened the doors to both massive scientific progress and ethical controversy. Now more than ever, were seeing that CRISPR still has massive kinks to work out. Can we ever fully understand the social and scientific implications of gene editing, and should we use it in humans before we learn how to properly harness it?

What is gene editing?

The 20th century saw genetic scientists increasingly focus their pursuits on the sub-microscopic. As science delved deeper into the human body in an attempt to uncover the molecular minutiae of life, the possibility of reaching into the cell and manipulating its genetic material began to look more and more real. Even by the 1950s, evidence had been mounting for decades that deoxyribonucleic acid (DNA), an unassuming molecule residing in a central cellular compartment called the nucleus, was the physical genetic material that passed information from parent to child. Finally, in 1953, landmark work by Kings College biochemist Rosalind Franklin allowed Cambridge researchers to reveal the structure of DNA and confirm its role in heredity once and for all.

Starting from a hesitant foundation, molecular genetics exploded in both scope and popularity over subsequent decades. With the secrets of heredity increasingly out in the open, human ambition demanded that we try to bend DNA to our willand now we can. These days, targeted gene editing techniques revolve around artificially-engineered molecular tools known as nucleases, whose earliest use was in 1996not even 50 years after the discovery of DNAs structure. Engineered nucleases are often described as molecular scissors. Fundamentally, they have two main parts: one part that finds and grabs onto the target DNA within a cell, and one part that snips a piece out of that DNA.

How CRISPR works

CRISPR is similar to other directed nucleases, but its much better at its job. The CRISPR part is secondary to the systems gene editing applications; the truly important discovery, which Jennifer Doudna made in 2012, was a protein that she called CRISPR-associated protein 9, or Cas9. This protein is the nuclease tool, the pair of molecular scissors that finds, sticks to, and snips target DNAand its more accurate than anything weve ever seen before.

In bacteria, CRISPR is a section of the genome that acts as an immune memory, storing little snippets of different viruses genetic material as DNA after failed infections, like trophies. When a once-active virus attempts to invade a bacterium, the mobile helper Cas9 copies down the relevant snippet from CRISPR in the form of ribonucleic acid, or RNA. RNA is a molecule thats virtually identical to DNA, except for one extra oxygen atom. Because of this property, the RNA sequence that Cas9 holds can pair exactly, nucleotide by nucleotide, with the viral targets DNA, making it extremely efficient at finding that DNA. With a freshly transcribed RNA guide, the bacterium can deploy Cas9 to findand cut outthe corresponding section of viral genetic material, rendering the attacker harmless.

The existence of CRISPR in bacteria was old news by 2012, but Doudnas discovery of Cas9s function was revolutionary. With a little creativity and ingenuity, such a simple and accurate nuclease can be modified to be much more than just a pair of scissors. Using synthetic RNA guides and certain tweaks, Cas9 can be used to remove specific genes, cause new insertions to genomes, tag DNA sequences with fluorescent probes, and much more.

The possibilities seem endless.What if we could go into the body of a human affected by a hereditary disease and change that persons DNA to cure them? What if we could modify reproductive germ cells in human bodies (which give rise to sperm and eggs), or make targeted genetic edits in the very first cell of an embryo? Nine months of division and multiplication later, that cell would give rise to a human being whose very nature has been deliberately tweakedand their childrens nature, and their childrens. With the accuracy and accessibility of the CRISPR/Cas9 system, these ideas arent hypotheticals. In 2019, CRISPR edits in bone marrow stem cells were successfully used to cure sickle cell anemia in a Mississippi woman. Beta thalassaemia, another genetic disease of the blood, has also been treated this way. In 2018, Chinese scientist He Jiankui even claimed that he had conferred HIV immunity upon twin girls using embryonic editing.

CRISPRs complications

At first glance, CRISPR looks like a miraclebut it isnt perfect. What if some cells were affected by edits, but others werent, creating a strange genetic mosaic in a human body? What if, in trying to modify a specific gene, we accidentally hit a different section of DNA nearby? What if we got the right gene, but it also affected a different part of the body that we didnt know about?

These problems arent hypotheticals either. So-called mosaicism and off-target editing are huge concerns among CRISPR scientists. Mosaicism is of particular concern in embryonic editing. Though CRISPR injections are carried out when an embryo is single-celled, CRISPR doesnt always appear to work until after several rounds of cell divisionand it doesnt work in every cell. If not all the cells in the body are affected by gene editing that is intended to eliminate a genetic disease, the disease could remain in the body. It may be possible to combat mosaicism with faster gene editing (so that cells dont replicate before theyve had a chance to become CRISPR-modified), altering sperm and egg cells before they meet to form an embryo, and developing more precise CRISPR gene editing which is in itself a challenge, thanks to off-target editing.

In nature, a little bit of off-target editing could actually make the CRISPR-Cas9 defense system stronger with the principle of redundancy. Flexibility in the form of imprecision could allow a bacterium to neutralize viruses whose exact genetic sequences have not yet been encountered: viruses related to, but not identical to, previous attackers. In clinical and therapeutic applications, on the other hand, precision is everything. And unfortunately, as time passes, CRISPRs level of precision seems further and further off. Preprints released just this year reveal that the frequency and magnitude of CRISPRs off-target edits in human cells may be worse than we had previously known. Large proportions of cells with massive unwanted DNA deletions, losses of entire chromosomes in experimental embryos, and shuffling of genetic sequences were observed.

Of course, not only do scientists need to avoid off-target edits, but they also need to know when such undesired edits have occurred. Off-target effects can be detected by genome sequencing and computer prediction tools, but theres no perfect way to do it yetthere may still be editing misses that were, well, missing. Off-target edits themselves could be minimized by altering the RNA transcript that Cas9 carries to make it more accurate, altering Cas9 itself, or reducing the actual amount of Cas9 protein released into the cell (though this could also reduce on-target effects). Replacing Cas9 itself with other Cas variants, like smaller and more easily deliverable CasX and CasY proteins, is a promising possibility for more efficient editing, but these candidates still run into many of the same problems as Cas9. More strategies are constantly being discovered, proposed, and explored, but were still nowhere near perfect.

Perhaps most importantly, even barring any purely technical problems, is that humans remain in sheer ignorance of much of the extent and consequences of pleiotropy, a phenomenon where a genes presence or deletion has more than one effect in the human body. Even genes whose function we think we know well might have totally unexpected additional functions. On the other side of the coin, we dont have a comprehensive understanding of how many different genetic contributors there are to any given trait or disease, much less where they lie in the genome. We dont understand the way that thousands of variations across the entire genome contribute to appearance, personality, and health. Assuming that some genes are good and others are bad is morally dangerous, and scientifically reprehensible. In reality, we are not ready for genetic determinism, and may never be.

A great responsibility

Humanity has discovered a great power, but we all know what comes with great power. Questions of which edits are necessary for health (is mild Harlequin syndrome a disease or a cosmetic concern?), whether edits are ethical (should autism and homosexuality be considered curable conditions?), and the possibility of designer babies, among others, are pertinent and require thorough discussion. We also need to realize that making these types of changes isnt our decision until we can get CRISPR right, and understand the genome well enough to target particular phenotypes. Though most scientists are aware of the difficulties of CRISPR and its use is generally tightly regulated, some scientistsand laypeopleare less careful. He Jiankuis apparent miracle HIV cure led to his arrest and imprisonment for unapproved and unethical practice. Its no great surprise that his work likely fell prey to off-target effects and mosaicism; even if he got it right, his intended change could alter cognitive function, and who knows what else?

Non-scientists are getting involved too: in 2018, self-proclaimed biohacker Josiah Zayner publicly injected his own arm with what he claimed was muscle-enhancing CRISPR. Though Zayner is one of the most vocal, hes not the only one of his kind. Quieter biohackers, untrained people without a scientific background or a good understanding of how CRISPR can go wrong, are attempting to edit themselves and even their pets.

Laypeople have an unquestionable place in science: the scientific discipline needs fresh perspectives and creativity that stuffy academics cant offer. CRISPR is still in its infancy, though. Before we know much, much more about its capabilities and consequences, there can be no place for black market gene editing kits, rogue scientists altering human embryonic and germline DNA, or basement geneticists injecting Cas9 into their dogs. Who can say what effects these interventions might have, not just on edited individuals, but on the futures of entire species?

Some say that gene editing is an act of hubris, destined to backfire spectacularly and horrendously. Others believe that its our responsibility to use CRISPR to improve lives. Which of these opinions is true depends on how science walks a narrow tightrope, though Im inclined to agree with the latterand add that our responsibility is not just to master gene editing, but to make clear and public its many faults and failings. The truth, in all its complexity, needs to overcome pop sciences oversimplification and sensationalism. Promising new advances and techniques are on the horizon, but we have a long way to go. Gene editing is no joke; humanity is playing with fire. With an incredibly accurate and accessible nuclease making its way into labs and garages across the world (while its flaws continue to be uncovered year by year), it is more important than ever for the world to understand and discuss the long-reaching consequences and responsible use of gene editing technology. CRISPR is not a miracle, but gene editing may very well be the future of humanityand its on us to keep it under control.

See the rest here:
The Trouble With CRISPR - Strand

Recommendation and review posted by Bethany Smith

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Orthopedic Regenerative Medicine Market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in future.

Whats keeping Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Request a Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/3566

List of Companies Mentioned:Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

1) Does Study provides Latest Impact on Market due to COVID & Slowdown?

Yes study have considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand current scenario.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the the report includes Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.. list is sorted to come up with a sample size of atleast 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, further breakdown in business segments by end use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014 2018

Base year 2018

Forecast period** 2019 to 2027 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Detailed Segmentation:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Global Orthopedic Regenerative Medicine Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Analysis of M&As, Partnership & JVs in Global Orthopedic Regenerative Medicine Industry in United States & Other Emerging Geographies

Top 10 Global Orthopedic Regenerative Medicine Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

Report Overview:It includes the Orthopedic Regenerative Medicine market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Orthopedic Regenerative Medicine market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Orthopedic Regenerative Medicine market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Orthopedic Regenerative Medicine market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Download PDF Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/3566

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

Mr Raj ShahCoherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone +1-206-701-6702[emailprotected]

Read this article:
Orthopedic Regenerative Medicine Market Insights and Business Outlook By Top Players Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Recommendation and review posted by Bethany Smith

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/23101

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/23101

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regionsviz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/23101

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

View original post here:
Global Amniotic Fluid Stem Cell Therapy Market to Witness Rapid Development During the Period 2018 2026 - Market Research Vista

Recommendation and review posted by Bethany Smith

A New Business Intelligence Report released by Data Bridge Market Research with title GlobalExosome Therapeutic Marketsize, share, growth, Industry Trends and Forecast 2027 has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Global Exosome Therapeutic Market Report offers energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. This report has been crafted as the result of persistent efforts lead by knowledgeable forecasters, innovative analysts and brilliant researchers who indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction for the business needs.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) For [emailprotected]:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market

DBMR Analyses that the Exosome Therapeutic Market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Increased number of exosome therapeutics as compared to the past few years will accelerate market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

KNOW YOUR OPTIONS IN THE FIGHT AGAINST COVID-19

The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

To Understand How COVID-19 Impact is covered in This Report. Get Sample Copy of the [emailprotected]https://www.databridgemarketresearch.com/request-covid-19/global-exosome-therapeutic-market

The Global Exosome Therapeutic market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Exosome Therapeutic Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Exosome Therapeutic manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

Major Players in Global Exosome Therapeutic Market Include

evox THERAPEUTICSEXOCOBIOExopharmAEGLE TherapeuticsUnited Therapeutics CorporationCodiak BioSciencesJazz Pharmaceuticals, Inc.Boehringer Ingelheim International GmbHReNeuron Group plcCapricor TherapeuticsAvalon Globocare Corp.CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC.Stem Cells Group..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market

New Exosome Therapeutic Market Developments in 2019

In January 2019, Codiak BioSciences has collaborated with Jazz Pharmaceuticals, Inc. to develop and commercialize exosome therapeutics to treat cancer. The collaboration will help the company to address issues which have been often implicated in solid tumors and hematological malignancies.

In October 2018, Avalon GloboCare Corp. has collaborated with Weill Cornell Medicine to form standards in cGMP-grade for human endothelial cells sourced exosome which is significant for organ regeneration and vascular health and isolation and identification of exosomes sourced from tissue for liquid biopsy and clinical use. The collaboration will help the company to lead market as exosome isolation system as will be first in the world for standardization processing of cGMP-grade exosomes for clinical studies.

In July 2018, Capricor Therapeutics has formed collaboration with the U.S. Army Institute of Surgical Research (USAISR) to discover potential for CAP-2003 (exosomes) in order to address trauma-related conditions and injuries. The collaboration will help to test CAP-2003 as a tool for preservation of life.

This research is categorized differently considering the various aspects of this market. It also evaluates the current situation and the future of the market by using the forecast horizon. The forecast is analyzed based on the volume and revenue of this market. The tools used for analyzing the Global Exosome Therapeutic Market research report include SWOT analysis.

The Global Exosome Therapeutic segments and Market Data Break Down are illuminated below:

By Type (Natural Exosomes, Hybrid Exosomes

By Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others)

By Therapy (Immunotherapy, Gene Therapy, Chemotherapy)

By Transporting Capacity (Bio Macromolecules, Small Molecules

By Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others)

By Route of administration (Oral, Parenteral)

By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes)

If you have any Enquiry please click here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market

The Global Exosome Therapeutic Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information.

What are the strengths and weaknesses of the key vendors?

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Scope of the Exosome Therapeutic Market

The global exosome therapeutic market is segmented on the basis of countries into U.S., Mexico, Turkey, Hong Kong, Australia, South Korea, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua and Uruguay.

All country based analysis of the exosome therapeutic market is further analyzed based on maximum granularity into further segmentation. On the basis of type, the market is segmented into natural exosomes and hybrid exosomes. Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. On the basis of therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. On the basis of transporting capacity, the market is segmented into bio macromolecules and small molecules. On the basis of application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. On the basis of route of administration, the market is segmented into pa oral and parenteral. On the basis of end user, the market is segmented into hospitals, diagnostic centers and research & academic institutes and others.

Some Points from Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Regulatory Scenario by Region/Country1.4 Market Investment Scenario Strategic1.5 Market Analysis by Type1.5.1 Global Exosome Therapeutic Market Share by Type (2020-2027)1.5.2 Type 11.5.3 Type 21.5.4 Other1.6 Market by Application1.6.1 Global Exosome Therapeutic Market Share by Application (2020-2027)1.6.2 Application 11.6.3 Application 21.6.4 Other1.7 Exosome Therapeutic Industry Development Trends under COVID-19 Outbreak1.7.1 Region COVID-19 Status Overview1.7.2 Influence of COVID-19 Outbreak on Exosome Therapeutic Industry Development

Global Market Growth Trends2.1 Industry Trends2.1.1 SWOT Analysis2.1.2 Porters Five Forces Analysis2.2 Potential Market and Growth Potential Analysis2.3 Industry News and Policies by Regions2.3.1 Industry News2.3.2 Industry Policies3 Value Chain of Exosome Therapeutic Market3.1 Value Chain Status3.2 Exosome Therapeutic Manufacturing Cost Structure Analysis3.2.1 Production Process Analysis3.2.2 Manufacturing Cost Structure of Exosome Therapeutic3.2.3 Labor Cost of Exosome Therapeutic3.3 Sales and Marketing Model Analysis3.4 Downstream Major Customer Analysis (by Region)

4 Players Profiles4.1 Player 14.1.1 Player 1 Basic Information4.1.2 Exosome Therapeutic Product Profiles, Application and Specification4.1.3 Player 1 Exosome Therapeutic Market Performance (2015-2020)4.1.4 Player 1 Business Overview4.2 Player 24.2.1 Player 2 Basic Information4.2.2 Exosome Therapeutic Product Profiles, Application and Specification4.2.3 Player 2 Exosome Therapeutic Market Performance (2015-2020)4.2.4 Player 2 Business Overview4.3 Player 34.3.1 Player 3 Basic Information4.3.2 Exosome Therapeutic Product Profiles, Application and Specification4.3.3 Player 3 Exosome Therapeutic Market Performance (2015-2020)4.3.4 Player 3 Business Overview4.4 Player 44.4.1 Player 4 Basic Information4.4.2 Exosome Therapeutic Product Profiles, Application and Specification4.4.3 Player 4 Exosome Therapeutic Market Performance (2015-2020)4.4.4 Player 4 Business Overview4.5 Player 54.5.1 Player 5 Basic Information4.5.2 Exosome Therapeutic Product Profiles, Application and Specification4.5.3 Player 5 Exosome Therapeutic Market Performance (2015-2020)

4.5.4 Player 5 Business Overview5 Global Exosome Therapeutic Market Analysis by Regions5.1 Global Exosome Therapeutic Sales, Revenue and Market Share by Regions5.1.1 Global Exosome Therapeutic Sales by Regions (2015-2020)5.1.2 Global Exosome Therapeutic Revenue by Regions (2015-2020)5.2 North America Exosome Therapeutic Sales and Growth Rate (2015-2020)5.3 Europe Exosome Therapeutic Sales and Growth Rate (2015-2020)5.4 Asia-Pacific Exosome Therapeutic Sales and Growth Rate (2015-2020)5.5 Middle East and Africa Exosome Therapeutic Sales and Growth Rate (2015-2020)5.6 South America Exosome Therapeutic Sales and Growth Rate (2015-2020)

11 Global Exosome Therapeutic Market Segment byTypes12 Global Exosome Therapeutic Market Segment by Applications13 Exosome Therapeutic Market Forecast by Regions (2020-2027)ContinuedComplete Report Is Available| Get Free TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market

Thanks for reading this article, we can also provide customized report as per companys specific needs. You can also get separate chapter wise or region wise report versions including North America, Europe or Asia.

Our Other Reports:-

Digital Forensics Market Size, Global Growth Analysis 2020, Technology Trends, Latest Innovation by Cellebrite, MSBA, OpenText Corp, Oxygen Forensics, Digital Forensics

Pharmacogenomics Market Size, Industry Analysis by Share, Dynamics, Global Trends, Future Growth Demand, Top Players: Abbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd: Says DBMR

Robotic Prosthetics Market 2020 Size, Industry Demand, Growth, Trends, Latest Tech & Innovation by Human Technology, HDT Global, SynTouch, Ottobock, Endolite

Care Services Market to Grow with 16.1% CAGR by 2027|Global Industry Size, Share, Growth & Latest Technology by EXL, Casenet, LLC, Medecision, IBM, Cognizant, Cerner

Generic Drug Market Size, Share, Growth, Industry Demand, Revenue, Competitive Outlook:-Pfizer, Teva Pharmaceutical, Lupin, Dr. Reddys Laboratories

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Contact:Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475[emailprotected]

Read more here:
Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, Trends, Share and Forecasts by 2027 - Bulletin...

Recommendation and review posted by Bethany Smith

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comWebsite:www.maximizemarketresearch.com

See the article here:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - WOLE TV

Recommendation and review posted by Bethany Smith

Best hair transplant clinics in the world

Hair restoration is a surgical performance which entails the removal of hair from an area known as the donor site to an area facing balding which is called the receiving site. This method is primarily used to counter alopecia in males as it is a less invasive technique which uses grafts containing grafts which have hair follicles that are genetically resistant to balding. These grafts are most often harvested from the back of the head. The harvested hair is then transplanted to the patchy region. Hair restoration can also be used to restore eyebrows, eyelashes, beard hair, pubic hair, and chest hair. Hair restoration is also possible in areas that have experienced hair loss as a result of scars from accidents or surgery, such as previous hair transplant surgery. There are two conventional methods for hair restoration hair transplanting and skin grafting. In a skin grafting procedure, the grafts harbour nearly all the dermis and epidermis neighbouring the hair follicles. A hair transplant involves numerous little grafts which are replaced instead of a distinct strip of skin.

Hair restoration is not a new pursuit. For instance, dating back to the 19th century is the use of scalp blinkers, such that a band of tissue containing the unique blood resource is allocated to another bald area. Back in 1897, Menahem Hodara successfully transplanted hair that was sourced from the unaffected regions of the scalp to the scars that were left bare by favus. The use of modern transplant methods started back in the 1930s, when the surgical team made use of small grafts and follicular unit grafts to substitute the impaired regions of the eyelashes and the eyebrows. Still, the method was not used to treat baldness. The surgeons continuous efforts did not receive any attention, and the traumas caused by World War II kept their discoveries unknown for the subsequent two decades.

The current age of hair restoration in the western world began in the late 1950s when the then New York-based Norman Orentreich started experimentation using free donor grafts to zones that had been faced by alopecia in patients experiencing male-related baldness. Earlier on, it was supposed that the restored hair would not flourish just like the unique hair in the receiving region.

Follicular Unit Extraction (FUE) is the favoured method for hair restoration. Dr. Asim Shahmalak, MD, hair transplant surgeon, broadcaster and founder of the Crown Clinic in Manchester, says 70% of his clients opt for the FUE method. The procedure takes about six to seven hours, with many clients going home the same day. Dr. Shahmalak explains: With FUE, specific follicles are detached from the back and side of the scalp and then transferred by a surgeon to the balding regions, which are mainly the top of the scalp. The benefit of this technique is that there is minimal scarring. The patients who opt for this method usually tend to heal after two weeks. FUE is predominantly appropriate for clients who like their hair short or shaved, as the scars are hardly noticeable. During the process, the giver part, which is usually the back of the scalp, is numbed with an anaesthetic. Then the donor follicles are detached separately, leaving behind minor scars where the hair is attached.

In the last few years, FUE has increased in popularity relative to Follicular Unit Transplantation (FUT). This can, in part, be attributed to the growing number of celebrities who have chosen FUE. FUE is also recommended for men who want to shave their heads or wear their hair short. The FUE technique is also faster, with an average of five hours to complete a procedure. This is because the extraction of hair from the hair follicles is quicker. FUE will also deliver a faster healing process than FUT, as in FUT a strip of skin is detached from a patient so as to get the donor hair rather than the separate follicles.

Best hair transplant clinics

CapilClinic, the largest private hospital group in Istanbul, specialises in hair transplantation. They are the leader in the field of hair transplants and the primary referral hospital recognised as the international model for the best service and results. CapilClinic began operations in 2015. The facility is known for its world-renowned medical staff, many of them with more than ten years of experience in hair transplantation procedures and patients from all over the world. The facility outshines the others as a result of its renowned specialists, top-notch facilities, state-of-the-art equipment, machinery and tools.

Dr Ouz Kayiran is a plastic surgeon, aesthetic surgeon and medical director at CapilClinic. As a plastic surgeon, he has over nine years experience in the industry, regularly takes part in cutting edge scientific research, and is featured in international publications.

The clinic has a luxury hotel used to accommodate its clients from abroad before they jet back to their home country. The hotel is located in the Kadky area of Istanbul, a large, populous and cosmopolitan district that boasts colourful murals, indie boutiques, hip cafes and Anatolian eateries. The hotel provides wireless internet in the rooms, business centre, meeting areas, and public areas.

As an added benefit to your luxury experience at CapilClinic, the hospital provides concierge airport transfers for its patients. CapilClinic will have a staff member at the airport waiting to receive you on arrival and then transfer you to the hotel. It is not uncommon on arrival in Istanbul for travellers to complain about long waits or delays at the airport. CapilClinic has removed that obstacle for its patients. Simply identify yourself to the waiting driver and enjoy a quick transfer to the hotel.

https://www.capilclinic.uk

Dr. Thomas Frist started the Hospital Corporation of America (HCA) in 1968. He had a dream to generate a healthcare institution with scope, expertise, and resources to provide the highest global standards of client care. HCA now has over 300 branches in the US and the UK and boasts 37,000 doctors, 240,000 nurses and a total of 27 million patient visits each year. Experienced staff strive to provide a quality of service and excellence that they desire for themselves, family members and loved ones.

HCA opened in the UK in 1995. Since that time, the institution has put up a world-class chain of more than thirty clinics in London and Manchester, equipped with modern diagnostic and handling equipment. In 2017, they expanded their operations to include diagnostic and outpatient services in Elstree, Chelsea, Marylebone, and Chiswick, thereby conveying high-quality services to those communities.

Patient care is the priority at the Harley Street Clinic. The clinic provides a variety of compound care for patients, through its specialisation in areas such as neurosciences for adults, children and babies, cardiology, and oncology. From heart surgery of newborn infants to the leading procedures for combating cancer, the technicians work in harmony to render exceptional service and treatments for their clients. The hospital also has one of the biggest private paediatric ICU units in Europe, with 12 beds. The paediatric ICU facilitates a variety of complicated treatments for babies and children, including thoracic and cardiac surgery, spinal surgery, and cancer care. The hospital is proud to be working with world-class experts who also have jobs in the UKs leading NHS teaching hospitals. Consultants, expert in their respective fields, have offices at the hospital; they look after their patients themselves throughout the entire treatment process.

Bernstein Medical is a renowned hair transplant clinic and also a referral centre devoted to the treatment of alopecia in both genders with the use of state-of-the-art technologies. It was founded by the worlds leading hair transplant developer, Dr. Robert M. Bernstein, back in the year 2005. The clinic is situated in midtown Manhattan, New York City. Hair restoration surgery at this clinic is conducted using the FUT and FUE methods, which were introduced by Dr. Bernstein. FUE technique is performed with the use of the mechanical hair transplant system. The clinic provides the best and highest level of care and treatment to the patients who visit them.

Dr. Bernstein is a pioneer of the current hair transplant surgery and founder of Bernstein Medical, which caters to all hair transplantation needs in New York City. Dr. Bernstein is globally recognised for having introduced the FUE and FUT to the medical community. These are the techniques that revolutionizsd the surgical hair restoration industry.

Bernstein Clinic offers the following services to its clients:

Located in Vancouver, Canada, the Hasson & Wong Clinic is proud of its results from hair transplant procedures. They feature their work on the company webpage with clear photos of real patients that have undergone hair restoration procedures at their clinic.

Hasson & Wong Clinic takes pride in the number of patients who, at their own initiative, have gone to the internet to document their positive experience and applaud the quality of their medical staff and facilities. The vast majority of their clients are pleased with the achieved results.

This clinic has acquired a global reputation for its consistency in offering excellent results. They welcome patients from all over the world, with approximately 50 per cent of the patients originating from Europe, Canada, the United States and Asia.

For hair restoration surgery, Hasson & Wong is one of the best hair restoration clinics to help patients achieve their desired goals.

Their team of professionals offer world-class service to the patients who visit the facility.

Dr. Jerry Wong graduated with a medical doctor degree from the University of Alberta. He then worked for many years as a GP at a hospital in Maple Ridge, Canada. In 1991, Dr. Dorman, a hair renewal surgeon based in Vancouver, ushered Dr. Wong into the field of hair restoration. Dr. Wong was excited about the microsurgical method of the technique. In 1992, he attended a hair transplant surgery school in Australia. On top of micro-mini grafting, he also obtained the necessary skills to perform lift and lap techniques and scalp reductions. Trained know-how in major scalp surgery is important for repair cases. Since then, the two doctors have remained to be great friends, taking part in conferences and occasionally sharing vacations.

Hasson & Wong Clinic is consistently able to work for long hours as a result of the experienced and dedicated team of surgeons. They have also been able to conduct massive mega sessions of hair restoration at their clinic with efficiency and safety, acquiring more than 5000 grafts over a single session. Their dedication to the development of hair restoration procedures is evidenced by the contribution they have made to the medical community.

Founded by Beverly Hills hair professionals Dr. George Abrahamian and Jacques Abrahamian, LA FUE Hair Clinic provide FUE hair renewal and FUE hair transplant services to patients who want a natural-looking final result. The clinic offers excellent services to its clients and prides itself on being the top choice for hair restoration needs. The doctors opened LA FUE Clinic after both having performed hair transplants for prominent people, including global celebrities, politicians, producers, musicians and successful businesspeople.

The LA FUE Hair Clinic offers a team of surgeons with over ten years of combined experience in the FUE hair transplant and FUE hair restoration field. As one of the few hair transplant clinics in Pasadena and the Los Angeles surrounding areas, the facility is proud to offer the best FUE Hair Transplant technique to help their clients get the look they desire.

The LA clinic offers the following services to its customers:

LA FUE Hair Clinic was founded with the mission of providing natural-looking hair renewal and restoration services to those suffering from alopecia. The clinic strives to be the first option for hair restoration services.

The editorial unit

More:
Best hair transplant clinics in the world - The Upcoming

Recommendation and review posted by Bethany Smith

Dublin, Aug. 04, 2020 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report ScopeThe report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/8msd9m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:
CRISPR Technology Market to Grow by 20.91% in 2020, Accelerated by the Outbreak of COVID-19 - Industry Projections to 2030 - GlobeNewswire

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report Scope

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/71fzdf

Read the original here:
Global CRISPR Technology Market Outlook 2020-2030 - Industry Driven by CRISPR Technology Being Used as a Diagnostic Tool for COVID-19 -...

Recommendation and review posted by Bethany Smith

Global CRISPR gene-editing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the CRISPR gene-editing market for Global, Europe, North America, Asia-Pacific, South America, and the Middle East & Africa.

Global CRISPR Gene-Editing Market report performs systematic gathering, recording and analysis of data about the issues related to the marketing of goods and services and serves the businesses with an excellent market research report. The report provides intelligent solutions to complex business challenges and commences an effortless decision-making process. The report analyses and evaluates the important industry trends, market size, market share estimates, and sales volume with which industry can speculate the strategies to increase return on investment (ROI). In the Global CRISPR Gene-Editing Market document, the statistics have been represented in the graphical format for an unambiguous understanding of facts and figures.

CRISPR gene-editing marketis rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Key Market Players:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the CRISPR Gene-Editing Industry

High prevalence of cancer worldwide is driving the growth of this marketJoint ventures by biotechnical companies for the advancement of genetic engineering for the development of CRISPR worldwide can also boost the market growthExpanding the application of CRISPR technology by innovative research from the different academic organizations also enhances the market growth

High finance in research and development also acts as a driving factor in the growth of this marketProbable mistreatment of CRISPR gene editing device and CRISPR/Cas genome editing device is restricting the growth for the marketScientific and major technical challenges for the production of disease specific novel CRISPR gene editing can also hamper the market growthLack of healthcare budget in some middle-income countries restricts the market growth

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

The titled segments and sub-section of the market are illuminated below:

By Therapeutic

OncologyAutoimmune/Inflammatory

By Application

Genome EngineeringDisease ModelsFunctional GenomicsOthers

By Technology

CRISPR/Cas9Zinc Finger NucleasesOthers

By Services

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System ProductsOthers

By Products

GenCrispr/Cas9 kitsGenCrispr Cas9 AntibodiesGenCrispr Cas9 EnzymesOthers

By End-Users

Biotechnology & Pharmaceutical CompaniesAcademic & Government Research InstitutesContract Research OrganizationsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

How will the report help new companies to plan their investments in the CRISPR Gene-Editing market?

The CRISPR Gene-Editing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crispr-gene-editing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Follow this link:
Global CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo...

Recommendation and review posted by Bethany Smith

The global CRISPR and Cas Genes Market Report 2020 was prepared to provide the market landscape and unlimited guidelines for the current market size, market share, driving factors, Trends, progressive growth and the dominant players of the CRISPR and Cas Genes Market . The report provides top manufacturers, distributors, dealers and dealers with general information about the market. It will help you to understand the product scope, the market overview, the driving force of the market, technological progress, market risk, opportunities and research results.

Market Report world has monitored the CRISPR and Cas Genes Market for the new Research Areas industrial market CRISPR and Cas Genes Market was valued at USD 1.35 Billion in 2019 and is projected to reach USD 4.53 Billion by 2027, growing at a CAGR of 16.36 % from 2020 to 2027.

Our Reports on the CRISPR and Cas Genes Market for the new Research Areas industrial market offer a holistic analysis, market size and forecast, Trends, growth drivers and challenges as well as a supplier analysis for about 25 suppliers.

To request an exclusive sample report for CRISPR and Cas Genes Market : https://www.verifiedmarketresearch.com/download-sample/?rid=40530&utm_source=PFS&utm_medium=001

Global CRISPR and Cas Genes Market research to 2020 provides a basic Overview of the industry including definitions, classifications, applications and structure of the industrial chain. The global CRISPR and Cas Genes Market report is provided for international markets as well as for development trends, competitive landscape analyses and the development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / Export consumption, supply and demand, costs, Price, Sales and gross margins.

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

This report examines the global CRISPR and Cas Genes Market and analyses and examines the IoT in Education development status and forecast in the US, EU, Japan, China, India and Southeast Asia. This report focuses on the highest players in the global CRISPR and Cas Genes Market .

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40530&utm_source=PFS&utm_medium=001

The scope of the report covers all major system technologies currently being implemented in the global IoT in Education industry. Market values are supported the Top User (public and private) supports the production of IoT in Education systems. CRISPR and Cas Genes Market manufacturers place orders as soon as they receive work orders from CRISPR and Cas Genes Market operators. Therefore, market figures are derived from the perspective of the top users taking into account their orders (CRISPR and Cas Genes Market operator) for the CRISPR and Cas Genes Market .

North America (USA, Canada and Mexico)

Europe (Germany, Great Britain, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia and Vietnam))

-South America (Brazil, etc.)

The Middle East and Africa (North Africa and GCC countries)

The CRISPR and Cas Genes Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

Market drivers

Increasing deforestation due to increasing demand for increasing raw materials

For a full, detailed list, see our report

Market Challenge

Risks associated with the use of IoT in Education

For a full, detailed list, see our report

Market Trend

Increasing consumer preference for IoT in EducationFor a full, detailed list, see our report

The global market research report of IoT in Education industry 2020 is distributed over several pages and contains exclusive Statistics, data, information, CRISPR and Cas Genes Market trends and details of the competitive landscape in this niche sector.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/crispr-and-cas-genes-market/?utm_source=PFS&utm_medium=001

-To analyze IoT in Education consumption (value and volume), product type and Application, History data from 2015 to 2020 and forecast.

-To understand the structure of the CRISPR and Cas Genes Market , identify the different sub-segments.

Focuses on the most important IoT in Education manufacturers to define, describe and analyze sales volume, value, market share, market competition landscape, STREBER analysis and development plans in the coming years.

To analyze the CRISPR and Cas Genes Market taking into account individual growth trends, future prospects and their contribution to the overall market

Detailed information on the key factors influencing the Expansion of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To analyze competitive developments such as extensions, agreements, product launches and acquisitions within the company

To strategically profile the main players and to comprehensively analyse their growth strategies.

The report also focuses on the worlds leading industry players in the global CRISPR and Cas Genes Market , providing information such as company profiles, product images and specifications, capacity, production, price, cost, revenue and contacting information. In addition, upstream raw materials and equipment as well as downstream demand analyses are managed. The global CRISPR and Cas Genes Market development trends and market channels are analyzed. Finally, the feasibility of the latest investment projects is evaluated and general research results are offered. With tables and figures to help analyze the global CRISPR and Cas Genes Market , this study provides important statistics on the state of the industry and can be a valuable guide and guidance for companies and individuals who are curious about the market.

This report provides a pinpoint analysis of the change in competitive dynamics

CRISPR and Cas Genes Market provides a forward-looking perspective on various factors that drive or inhibit market growth.

It includes a six-year forecast, which is assessed on the basis of expected market growth

Better understanding of the effects of specific conditions on the prevailing population of the CRISPR and Cas Genes Market .

To understand the most important product segments and their future

Transfer of more accurate information for clinical trials to determine research size and realistic recruitment for different countries

CRISPR and Cas Genes Market helps with sound business decisions by having complete insights into the market and analyzing market segments in depth

-To provide distinctive graphics and exemplary STREBER analysis of the most important market segments

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

More here:
CRISPR and Cas Genes Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2027 - Owned

Recommendation and review posted by Bethany Smith

A recently published market research report by Fact.MR on the CRISPR and Cas Genes Market depicts a crystal clear view of the market over the considered period of assessment (2020 2026). The global CRISPR and cas genes market study comes with an all in all compilation of the future, existing, and historical outlook of the market as well as the factors bringing in such growth for the market. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities, and threats of each CRISPR and cas genes market player in a comprehensive way. Further, the CRISPR and cas genes market report emphasizes the adoption pattern of the CRISPR and cas genes across various industries.

The existing trends, restraints, opportunities, and market drivers are studied thoroughly to offer a clear, 360-degree understanding of the existing landscape prevailing in the CRISPR and cas genes market. The research paints a detailed picture of how the market is likely to take shape in the coming years given the influence of current drivers, opportunities, and restraints. In this latest market research study published by Fact.MR, the analysts have taken into account the CRISPR and cas genes market from a local as well as global viewpoint.

Act Today to Succeed Tomorrow, Know the COVID-19 Impact, Request for Sample @https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The outbreak of novel coronavirus across the globe has changed the way about how we do business, it has resulted in both disadvantages and advantages for players operating in the CRISPR and cas genes market. A health crisis of enormous proportion, COVID-19 has emerged as a pandemic that would cause a restructuring of the world economy as well as social order. This outbreak is clearly going to characterize the coming era with fundamental schism. Many companies have shifted from their traditional methods of advertising during the lockdown period.

Taking help of this latest offering on the CRISPR and cas genes market by Fact.MR, the market players, suppliers, distributors, and other stakeholders can formulate innovative strategies based on their understanding of the pandemic and our report to expand their business and widen their base of customers. This research study by Fact.MR is likely to detail the factors that could impact the sales of products/ services in the global market landscape. The report is also likely to suggest avenues of growth that could boost sales in the post-pandemic era.

According to the market research report, the CRISPR and cas genes market is estimated to register a CAGR growth of 21.2% over the assessment period due to several key factors that is likely to influence the market, such as favorable regulatory policies, augmented spending on research and development. The analysts at Fact.MR makes use of the latest research methodologies while gathering data from credible and reliable sources, both primary and secondary, to prepare and present the market study.

In this CRISPR and cas genes market study, the following years are considered to project the market footprint:

The CRISPR and cas genes market report has answers to important questions, which include the following:

The CRISPR and cas genes market report covers the following regions:

On the basis of product type, the CRISPR and cas genes market report considers the following segments:

On the basis of end-use, the CRISPR and cas genes market report includes:

Ask for Regional Data of This Report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Prominent CRISPR and cas genes market players covered in the report contain:

The behavioral pattern of each of the market player, such as acquisitions, new product launches, partnerships, and mergers have been thoroughly studied to offer a detailed view of the competitive landscape of the CRISPR and cas genes market.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

See the rest here:
Scaling the COVID-19 Impact: Fact.MR Projects Staggering Growth in CRISPR and Cas Genes Market 2020 2026 - The Cloud Tribune

Recommendation and review posted by Bethany Smith

IndustryGrowthInsights (IGI) offers a detailed report on Global CRISPR Genome Editing Market. The report is a comprehensive research study that provides the scope of CRISPR Genome Editing market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in regions for the forecast period from 2020 to 2026. This report highlights key insights on the market focusing on the possible requirements of the clients and assisting them to make right decision about their business investment plans and strategies.

The CRISPR Genome Editing market report also covers an overview of the segments and sub-segmentations including the product types, applications, companies and regions. This report further includes the impact of COVID-19 on the market and explains dynamics of the market, future business impact, competition landscape of the companies, and the flow of the global supply and consumption. The report provides an in-depth analysis of the overall market structure of CRISPR Genome Editing and assesses the possible changes in the current as well as future competitive scenarios of the CRISPR Genome Editing market.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=136905

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies. IndustryGrowthInsights (IGI) is known for its data accuracy and granular market reports.

The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the CRISPR Genome Editing market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the CRISPR Genome Editing market.

Key companies that are covered in this report:

Editas MedicineCRISPR TherapeuticsHorizon DiscoverySigma-AldrichGenscriptSangamo BiosciencesLonza GroupIntegrated DNA TechnologiesNew England BiolabsOrigene TechnologiesTransposagen BiopharmaceuticalsThermo Fisher ScientificCaribou BiosciencesPrecision BiosciencesCellectisIntellia Therapeutics

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

Biotechnology CompaniesPharmaceutical CompaniesOthers

By Type:

Genetic EngineeringGene LibraryHuman Stem CellsOthers

As per the report, the CRISPR Genome Editing market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% through the forecast period (2020-2026). The report describes the current market trend of the CRISPR Genome Editing in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on CRISPR Genome Editing market.

You can buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=136905

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

CRISPR Genome Editing Market Overview

Global CRISPR Genome Editing Market Analysis and Forecast by Type

Global CRISPR Genome Editing Market Analysis and Forecast by Application

Global CRISPR Genome Editing Market Analysis and Forecast by Sales Channel

Global CRISPR Genome Editing Market Analysis and Forecast by Region

North America CRISPR Genome Editing Market Analysis and Forecast

Latin America CRISPR Genome Editing Market Analysis and Forecast

Europe CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Application

Middle East & Africa CRISPR Genome Editing Market Analysis and Forecast

Competition Landscape

Why you should buy this report?

This report offers a concise analysis of the CRISPR Genome Editing market for the last 5 years with historical data & more accurate prediction for upcoming 6 years on the basis of statistical information.

This report helps you to understand the market components by offering a cohesive framework of the key players and their competition dynamics as well as strategies.

The report is a complete guideline for the clients to arrive an informed business decision since it consists of a detailed information for better understandings of the current & future market situation.

The report also answers some of the key questions given below:

Which end-user is likely to play a crucial role in the development of the CRISPR Genome Editing market?

Which regional market is expected to dominate the CRISPR Genome Editing market in 2020-2026?

How is consumer consumption behavior impacting the business operations of market players in the current scenario of the CRISPR Genome Editing market?

If you have any questions on this report, please reach out to us @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=136905

About IndustryGrowthInsights (IGI):

We possess expertise in a variety of business intelligence domains. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://industrygrowthinsights.com

See original here:
CRISPR Genome Editing Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Market Research Vista

Recommendation and review posted by Bethany Smith

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Read the original:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

Recommendation and review posted by Bethany Smith

The U.S. Air Force could expand its current F-15EX procurement plans in order to replace its F-15E Strike Eagles, according to official documentation. The service currently aims to recapitalize its aging F-15C/D air superiority fighters with the new F-15EX as a priority, but it has also left the door open to replacing its Strike Eagles with the type. Such an initiative wouldn't come without controversy though, especially in terms of threatening the Air Force's long-held, but often questioned F-35A procurement number goal of 1,763 airframes.

The Justification and Approval (J&A) document lays out the USAFs case for buying the F-15EX. It says: The objective of this program is to rapidly develop, integrate, and field the F-15EX weapon system to refresh/replace aging F-15C/D aircraft. A decision to also refresh F-15E aircraft has not yet been made, but remains an option.

The report sets out the Air Force's reasoning for the sole-source contract being awarded to Boeing for F-15EX, and it was signed off by USAF acquisition chief Dr. William Roper in August 2019. It carefully lays out the urgent plans to replace an F-15C fleet that it is running out of airframe hours. It adds: The F-15 fleet is in dire need of a refresh, in particular the F-15C/D fleet, which without an expensive service life extension, will run out of airframe flying hours in [redacted}. In keeping with major recapitalization projects, the timing would suggest that, when it comes, the need to replace the Strike Eagle will be just as urgent as it is currently for the F-15C/D.

You can check out the document for yourself here:

The first production-standard F-15E Strike Eagle made its maiden flight on December 11, 1986, from McDonnell Douglas St Louis, Missouri, plant. The first of 236 production Strike Eagles was handed over to the 461st Tactical Fighter Training Squadron Deadly Jesters on April 12, 1988. The first operational unit the 336th Tactical Fighter Squadron (TFS) Rocketeers started to receive Strike Eagles at Seymour Johnson Air Force Base, North Carolina, in December 1988. The type was famously thrust into combat for Operation Desert Storm in 1991.

National Museum of the United States Air Force

Prior to the first true F-15E's first flight, a TF-15A (F-15B) was used to prove the Strike Eagle concept, acting as a prototype and capabilities demonstrator.

Strike Eagle serial 89-0487 from Seymour Johnson became the first example to reach 12,000 flight hours on August 16, 2016. The F-15E was beefed-up in comparison to the F-15C in order to carry a heavy weapons loads, however, like the Eagle, the youngest of which is 35 years old, the Strike Eagles are aging airframes.

The small 219-strong Strike Eagle fleet remains in high demand with an enduring commitment in the U.S. Central Command region that leverages many impressive niche capabilities. With just six front line Strike Eagle squadrons, at least one is always deployed. The F-15E is also capable of delivering nuclear weapons and is the first jet certified to employ the newest variant of the B61 tactical nuclear bomb.

The current F-15E fleet features two different engine classes. The oldest jets feature the Pratt & Whitney F100-PW-220E with roughly 23,500lbs of thrust. The younger models feature the P100-PW-229 engines with around 29,000lbs of thrust, making them the most capable of the lot by a serious margin. They are also the most numerous. The F-15EX is set to receive the F110-GE-129 engine that also has 29,000lbs of thrust.

USAF

Buying more F-15EXs to replace the current F-15E would be hugely significant. USAF Chief of Staff Gen. David L. Goldfein has made regular assertions that the F-15EX will not impact the F-35 Lightning II program, but switching later F-35 procurement targeted at replacing the F-15E to the F-15EX could impact the overall F-35A projected inventory requirement. Moreover, the Boeing fighter has been used as a means to pile competitive pressure on Lockheed Martin to reduce F-35 procurement and through-life costs.

The J&A report underscores the reasoning behind purchasing the F-15EX in terms of ease of transition: Refreshing the existing F-15 fleet (versus transitioning to a new advanced fighter aircraft) with F-15EX will dramatically reduce disruption to the logistics and sustainment infrastructure, as well as operational training and Mission Ready status of current F-15 units, by taking advantage of inherent familiarity with the existing aircraft, which will allow focus on the new and improved systems.

Boeing

The case for the urgent replacement of the F-15C/D includes reasons regarding safety. The schedule impact if there is no refresh is exacerbated by the fact that the average age of the F-15C/D fleet is 35 years. The fleets structural integrity is rapidly degrading due to the high-g flight profile used during training and operations. One wing commander imposed a G restriction due to a loss of confidence in the safety of the fleet.

The USAF examined a service life extension for the F-15C but this was ruled out as not being cost-effective. The speed with which Boeing can build the F-15EX is cited as another key differentiator. Based on the foreign investment in the Saudi Arabian F-15SA and Qatari F-15QA projects, the USAFs F-15EX will share 90-95 percent commonality with the Qatari jets, but it will receive some USAF-specific additions such as Eagle Passive/Active Warning and Survivability System (EPAWSS).

USAF

The report adds that buying the F-15EX will save the USAF $3 billion over the Future Years Defense Program compared to replacing that fleet with F-35s by avoiding significant transition costs required for a new aircraft. It adds: The USAF estimates that it will take six months or less to transition from the F-15C/D to the F-15EX given the significant commonality between the F-15C/D and F-15EX aircraft components and ground support equipment, while the transition time from F-15s to the F-35 (or any other airframe) will take approximately 18 months for an Active Duty squadron and 36 months for an Air National Guard squadron. Accordingly, from both an economic and readiness perspective, no other aircraft will satisfy the USAF requirement to refresh the F-15C/D fleet.

In addition, the document makes it clear that the premium once placed on an all stealth tactical fighter fleet has eroded: The USAF has determined that a mix of 4th generation capacity and 5th generation capability is necessary in balancing near and mid-term readiness with future needs.

These were all reasons we discussed as per the justification for the 'F-15X' when The War Zone broke the story of its existence two years ago.

USAF

There are no official plans to replace the F-15E when it is retired from service, and officially it could remain in service through life-extension programs. Yet, based on the situation facing the F-15C/D, it could be up for replacement as early as the end of the decade. Previously, the War Zone was told that the F-15EX is intended to directly replace the USAF's entire F-15C/D fleet. It would have no impact on the existing F-15E Strike Eagle fleet or its planned upgrade pathway that is underway now.

The F-15E shares similar cutting-edge technology as is being fielded in the F-15EX. It has been upgraded with the Raytheon AN/APG-82(v)1 Active Electronically Scanned Array (AESA) radar, the new Advanced Display Core Processor (ADCP) II, and it too is receiving the new EPAWSS self-protection system.

The current F-15EX procurement plan as set out earlier this month could be worth up to $22.9 billion over 10 years. This cost ceiling is based on a March 2019 F-15 SPO Rough Order of Magnitude (ROM) estimate for the maximum quantity of 200 aircraft. However, the report says procurement quantities will be established at a Most Probably Quantity (MPQ) of 144 aircraft. Still, this is seen as minimum fleet size, and it is likely to reach near or at the 200 level just in regards to replacing the F-15C/D fully.

USAF

The youngest F-15C/D in the USAF's fleet is 35 years old.

The current F-15C/D fleet of approximately 245 aircraft would be replaced on what would be close to a one-for-one basis if all options are exercised. While the report doesn't discuss actual numbers, it would suggest the similarly sized F-15E fleet could be recapitalized under a very similar model, which would take F-15EX procurement out to roughly 400 aircraft.

A USAF spokesman toldAir Force Magazine That decision has not been made, regarding the F-15E. A common F-15EX fleet in a merged Eagle community would have its benefits both logistically and operationally. There is also bound to be some tension between the F-15C/D units, the vast majority of which are Air National Guard, and the active-duty F-15E community under the current procurement plan for the F-15EX.

As the plan sits, the F-15EX would equip squadrons whose only missions have been air-to-air combat and air sovereignty with the most advanced and reliable multi-role F-15s in the entire force. In other words, the F-15E community, which is tasked with some of the most complex combat operations abroad, would be flying aging, partially upgraded jets while the Guard has brand new F-15EX with excess capabilities. This has raised the question of why doesn't the F-15E get replaced with the F-15EX and the current F-15C/D community receive surplus F-15Es?

USAF

F-35As and F-15Es in formation.

With over 50 years of production, the F-15 is entering into uncharted territory for fighter aircraft manufacturing. Boeing has cleverly retained credibility through reinventing the F-15 via foreign investment. With at least 144 new F-15s entering the Air Force's fleet in the near term, some 16 years after its last new Eagle was delivered, the prospects for follow-on orders are certainly there. This doesn't mean that recapitalizing the Strike Eagle fleet with F-15EX is anywhere near a done deal, but the door is open and it might just prove to be another case of the swiftest, cheapest, and most sensible way to keep some of the Air Force's most important fighter squadrons in business.

Regardless, with the F-15EX's stated service life of a whopping 20,000 hours, the Eagle will be gracing American fighter wing ramps well into the second half the century.

Contact the editor: Tyler@thedrive.com

Read more:
Let's Talk About The Air Force Potentially Replacing The F-15E With The F-15EX - The Drive

Recommendation and review posted by Bethany Smith

The Marine Corps amphibious vehicle involved in a deadly mishap Thursday has a long history and was set to be replaced a decade ago. However, defense budget cuts scrapped its multi-billion-dollar replacement in 2011.

Amphibious vehicles commonly called "Amtracks" have been part of the Marine Corps' fighting force since World War II, when in 1943 they carried Marines onto the shores of Tarawa, a tiny island in the Pacific.

The modern version, the Assault Amphibious Vehicle, entered service in 1972.

Related: Marine Corps identifies Marines and sailor presumed dead after amphibious assault vehicle accident

The armored troop carriers can be armed with a .50 caliber machine gun and a grenade launcher. They deploy from Navy amphibious ships' well decks to ferry troops to nearby beaches. On land, they're outfitted with tank treads and can transport assault teams to and from the battlefield before returning to their ships. They can carry up to 21 troops and are operated by a crew of three.

At the turn of the 21st century, replacing the AAV became the top priority for the Marines.

Its planned replacement, the Expeditionary Fighting Vehicle, was a larger, faster version of the AAV. It could travel at speeds over 25 mph while at sea more than triple the AAV's top speed of 8 mph in the water.

However, the technology in the EFV was expensive, and throughout the first decade of the 2000s costs ballooned for the General Dynamics-made craft. By 2011, the program cost was an estimated $15 billion. The program was canceled in January of that year.

Then-Congressman Duncan Hunter said at the time the cut would do "more harm than good, especially when the core competency of the Marine Corps centers on amphibious operations."

Hunter, a Marine veteran of the war in Iraq, left Congress in January after pleading guilty of stealing money from his campaign.

A cheaper replacement the Amphibious Combat Vehicle is still in the early stages of funding and development.

Lt. Gen. Joseph Osterman, the outgoing commanding general of I Marine Expeditionary Force, said at a Camp Pendleton news conference Friday that, despite its age, the AAV has been modernized since 1972.

"AAVs were originally procured in 1972 but they've gone through many service life extension programs," Osterman said. "They bring it in, they literally bring it down to just the hull and rebuild everything inside of it. We've done that multiple times through the years."

2020 The San Diego Union-Tribune. Distributed by Tribune Content Agency, LLC.

Here is the original post:
Marine Corps amphibious assault vehicle involved in deadly mishap was set to be replaced a decade ago - Task & Purpose

Recommendation and review posted by Bethany Smith

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Calcium is an important mineral thats crucial for maintaining bone strength and structure (1).

Whats more, its involved in many other aspects of health and required for blood clotting, muscle contractions, and nerve cell function (2).

Although calcium is found in a variety of foods like dairy products, nuts, seeds, and leafy greens, some people may need to supplement with it to help meet their daily needs.

However, selecting a high quality calcium supplement can be challenging, especially if youre not sure what to look for.

This article evaluates calcium supplements based on the following criteria:

Here are the 10 best calcium supplements of 2020.

General price ranges with dollar signs ($ to $$$) are indicated below. One dollar sign means the product is rather affordable, whereas three dollar signs indicate a higher price range.

Generally, prices range from $0.07$0.93 per serving, or $10.40$38 per container, though this may vary depending on where you shop.

Most products require you to just take 1 capsule daily, but some have a greater serving size.

Pricing guide

Price: $

This supplement contains 600 mg of calcium in the form of calcium carbonate, a compound that contains a high amount of calcium in each dose (3).

Calcium carbonate is not only more widely available than other forms but also often more affordable.

This product likewise contains vitamin D, which can help increase the absorption of calcium in the body (4).

Additionally, its verified by United States Pharmacopeia (USP), a third-party organization that tests supplements for purity and potency

Shop for Nature Mades Calcium online.

Price: $$

Packing 300 mg of calcium into a single serving, this high quality supplement features calcium citrate, a form of calcium thats very well absorbed by the body (5).

In addition to being hypoallergenic and made without the use of genetically modified organisms (GMOs), this calcium supplement is certified gluten-free, making it a great option for those with food sensitivities or celiac disease.

Its also produced in a facility thats Good Manufacturing Practice (GMP) certified by NSF International, meaning that it adheres to strict standards for quality and strength.

Shop for Pure Encapsulations Calcium Citrate online.

Price: $$

This product is made using calcium carbonate, a type of calcium thats often cheaper and more widely available than other forms.

It contains 600 mg of calcium per serving, providing nearly half of the calcium that you need in an entire day (6).

This supplement is also vegan and NSF Certified for Sport, meaning that it has undergone third-party testing to verify the formulation and purity of the product.

Shop for Vega Sport Pros Calcium online.

Price: $

This supplement not only contains 750 mg of calcium from calcium carbonate in each serving but also a hearty dose of vitamins D and K.

Both vitamin D and vitamin K are important for bone health and the prevention of conditions like osteoporosis, or bone loss (7, 8).

Additionally, vitamin D can help increase the absorption of calcium to help maintain bone strength (4).

This product is verified by USP as well, which can ensure that youre getting the highest quality possible.

Shop for Nature Mades Calcium 750 mg + D + K online.

Price: $

This supplement contains 200 mg of calcium in the form of highly absorbable calcium citrate (5).

It also contains 2.5 mcg of vitamin D, which can help increase the absorption of calcium and promote bone health (4).

Its produced by Life Extension, a company known for manufacturing high quality supplements.

Additionally, a certificate of analysis (COA) is available for all Life Extension products. A COA provides in-depth information about each supplement.

Shop for Life Extensions Calcium Citrate with Vitamin D online.

Price: $$

Thorne Research is a reputable supplement manufacturer and one of the few companies certified by the Therapeutic Goods Administration (TGA), an Australian government agency responsible for regulating supplements for safety and quality.

With calcium, vitamin D, magnesium, and vitamin K, this product is a great option for those looking to support bone health.

Shop for Thornes Basic Bone Nutrients online.

Individuals at risk of osteoporosis, those with certain medical conditions, and people who are unable to meet their calcium needs through food may require higher dosages of calcium (9).

However, its important to talk to your healthcare provider before using a high dose calcium supplement to prevent any adverse health effects.

Additionally, be sure to split your total daily dosage and take several smaller doses throughout the day. This is because calcium absorption is highest in doses of 500 mg or less and decreases with larger amounts (10).

Price: $$$

This product provides 1,300 mg of calcium per serving, making it a great option for those seeking a high dose calcium supplement.

It contains calcium carbonate derived from eggshells, as well as several other nutrients to support bone health, including vitamins D and K (7).

This product is also certified gluten-free, kosher, non-GMO, and organic.

Shop for Garden of Lifes Dr. Formulated Stronger Bones online.

Price: $

Each serving of this supplement boasts 1,000 mg of calcium, which is derived from a combination of calcium carbonate, calcium citrate, and calcium ascorbate.

Some older animal studies show that calcium ascorbate, a compound that contains both calcium and vitamin C, may be as well absorbed as other forms of calcium in the body (11, 12).

It also contains magnesium, a mineral thats essential to bone health and has been associated with increased bone mineral density (13, 14).

In addition to being vegan, kosher, and soy-free, its certified by Underwriters Laboratories (UL), which is a nonprofit organization that evaluates the safety of supplements.

Shop for NOW Supplements Calcium & Magnesium online.

Price: $

For those who prefer calcium gummies over capsules and tablets, this product may be a good choice.

It contains 500 mg of calcium, along with vitamin D to help maximize absorption.

It has also undergone third-party testing to evaluate its purity and strength, and it has been verified by USP.

Shop for Kirkland Signatures Calcium 500 mg with D3 online.

Price: $$$

These wafers offer 200 mg of calcium per serving and can be an easy way to bump up your intake of calcium.

Standard Process is a unique manufacturer that grows 80% of the plants used in their supplements on their own certified organic farm.

They also use comprehensive testing methods that have been approved by third-party organizations like USP and the Association of Analytical Communities to maximize quality.

Shop for Standard Process Calcifood online.

With so many different supplements on the market, picking the right product can be challenging.

Be sure to buy from a reputable manufacturer and look for supplements that have undergone third-party testing and are certified by organizations like USP or NSF International.

Its also important to consider the type of calcium in your supplement and whether it contains calcium carbonate or calcium citrate, which are the two most common forms.

Calcium carbonate is more widely available, cheaper, and contains a higher amount of calcium than other compounds. However, it has been associated with symptoms like gas and bloating (3, 15).

Calcium citrate, on the other hand, is slightly more expensive but also more easily absorbed in the body (5, 15).

People who have low stomach acid or are taking proton pump inhibitors should choose calcium citrate, as it can be absorbed without the help of stomach acid (16).

Be sure to check the ingredient label carefully, as many products contain high amounts of fillers, additives, artificial sweeteners, and preservatives.

Many products also contain added ingredients like vitamin D, which can help optimize the absorption of calcium (4).

Calcium requirements range from 1,000-1,200 mg daily for most adults depending on age and sex, and it can come from a combination of food sources and supplements (17).

For most people, supplements providing 200500 mg of calcium are often enough to help fill any gaps in their diet (18).

However, those who are at risk of osteoporosis or unable to meet their calcium needs due to food allergies or dietary restrictions may require a higher dose (9).

Furthermore, those with certain medical conditions, such as hypoparathyroidism a condition characterized by low production of parathyroid hormone, may also need a higher dose supplement (19).

Be sure to talk to your doctor before using a high dose calcium supplement, and remember to always split supplementation into several smaller doses of less than 500 mg to maximize absorption (17).

Finally, its important to only use a supplement as directed and talk to a healthcare professional before starting to supplement, especially if you have any underlying conditions or are taking medications.

Check out these two articles to help make supplement shopping a breeze:

Calcium is an important mineral that plays a central role in bone health.

There are many calcium supplements on the market, each of which varies based on the type of calcium, dosage, and ingredients it contains.

When selecting a calcium supplement, be sure to consider all of these factors and look for products that have undergone third-party testing to ensure that youre getting the highest quality possible.

See original here:
The 10 Best Calcium Supplements of 2020 - Healthline

Recommendation and review posted by Bethany Smith